Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/78rxx503

A PROSPECTIVE STUDY TO ASSESS THE EFFECTIVENESS OF PRE-EMPTIVE ANALGESIA USING TRAMADOL VERSUS FENTANYL ON POST-OPERATIVE PAIN MANAGEMENT IN ORTHOPEDIC SURGERY PATIENTS

Dr. Manoj Kantilal Parikh*

**Assistant Professor, Department of Anaesthesia, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, Krishna, AP, Email- monojparikh3@rediffmail.com*

Accepted 08 October 2015 *Published 12 November 2015*

Abstract

Introduction: Pre-emptive analgesia prevents central sensitization by administering analgesics before noxious stimuli. This study compared the effectiveness of tramadol versus fentanyl for pre-emptive analgesia in orthopedic surgery patients, addressing the need for optimal perioperative pain management strategies with minimal adverse effects.

Methods: A prospective, randomized, double-blind, controlled trial was conducted at Dr. Pinnamaneni Siddhartha Institute of Medical Sciences from April to September 2015. Ninety patients undergoing elective orthopedic surgery were randomly allocated to receive tramadol 2 mg/kg (n=30), fentanyl 2 μg/kg (n=30), or normal saline placebo (n=30) intravenously after anesthesia induction. Primary outcomes included Visual Analog Scale pain scores, rescue analgesic requirements, and adverse events over 24 hours postoperatively.

Results: Both active treatments significantly reduced pain scores compared to control ($p<0.001$). Fentanyl provided superior early analgesia at 1-2 hours postoperatively, while tramadol demonstrated longer duration of effect with time to first rescue analgesia of 6.8±2.4 hours versus 4.2±1.8 hours for fentanyl ($p<0.001$). Tramadol group required fewer total rescue analgesics (2.3±1.4 vs 3.1±1.6 doses, $p<0.05$) and had significantly lower incidence of sedation (13.3% vs 46.7%), respiratory depression (0% vs 10.0%), and pruritus (6.7% vs 26.7%) compared to fentanyl. Patient satisfaction scores were highest in tramadol group (4.2±0.8 vs 3.8±0.9, $p<0.05$).

Conclusion: Both tramadol and fentanyl provide effective pre-emptive analgesia, but tramadol offers superior sustained pain relief with fewer adverse effects, making it the preferred choice for orthopedic surgery pre-emptive analgesia protocols.

Keywords: Pre-emptive analgesia, Tramadol, Fentanyl, Orthopedic surgery, Postoperative pain management

Introduction

Post-operative pain management remains a fundamental challenge in orthopedic surgery, significantly influencing patient outcomes, recovery trajectories, and overall satisfaction with surgical care. The traditional approach of treating pain reactively after it has developed often proves inadequate, leading to increased morbidity, prolonged hospital stays, and compromised rehabilitation efforts. This has prompted healthcare professionals to explore proactive strategies, with pre-emptive analgesia emerging as a promising paradigm shift in perioperative pain management.

Pre-emptive analgesia is predicated on the administration of analgesic agents before the initiation of noxious stimuli to prevent the establishment of central sensitization and subsequent amplification of pain signals. This concept was first introduced by Crile in 1913 and later refined by Wall in 1988, who demonstrated that pre-treatment with analgesics could prevent the development of central sensitization and wind-up phenomena that typically occur following tissue injury. The theoretical foundation rests on blocking nociceptive transmission at multiple levels of the nervous system before surgical incision, thereby preventing the cascade of neurochemical changes that lead to enhanced pain sensitivity.

The efficacy of pre-emptive analgesia has been demonstrated across various surgical specialties, with particular relevance to orthopedic procedures where extensive tissue manipulation and bone involvement typically result in severe postoperative pain. Orthopedic surgery presents unique challenges due to the inherent pain sensitivity of bone and periosteal structures, combined with the often extensive nature of surgical procedures. Patients undergoing orthopedic interventions frequently experience moderate to severe pain that can persist for days to weeks, significantly impacting their ability to participate in crucial early mobilization and rehabilitation programs.

Among the various analgesic agents available for pre-emptive administration, tramadol and fentanyl have gained considerable attention due to their distinct pharmacological profiles and proven efficacy in perioperative settings. Tramadol, a centrally acting analgesic introduced in the 1970s, offers a unique dual mechanism of action that combines weak μ-opioid receptor agonism with inhibition of norepinephrine and serotonin reuptake. This distinctive pharmacological profile provides effective analgesia while potentially minimizing the adverse effects commonly associated with traditional opioids, such as respiratory depression, sedation, and gastrointestinal disturbances.

The analgesic efficacy of tramadol has been extensively documented in various clinical settings, with studies demonstrating its effectiveness comparable to morphine for moderate to severe pain while maintaining a superior safety profile. Arici and colleagues (2004) highlighted tramadol's particular utility in orthopedic surgery, noting its efficacy in managing postoperative pain with fewer severe side effects compared to conventional opioids. The drug's unique pharmacokinetics, including its active metabolite O-desmethyltramadol, contribute to its sustained analgesic effect and make it particularly suitable for pre-emptive administration.

Fentanyl, a potent synthetic opioid agonist developed in the 1950s, represents the gold standard for perioperative analgesia in many clinical scenarios. Its rapid onset of action, high potency, and predictable pharmacokinetic profile have established it as a cornerstone of modern anesthetic practice. Fentanyl's ability to provide profound analgesia with relatively short duration of action makes it ideally suited for intraoperative use and early postoperative pain management. However, concerns regarding its potential for respiratory depression, particularly in elderly patients or those with comorbidities, have prompted exploration of alternative approaches.

The comparative effectiveness of tramadol versus fentanyl for pre-emptive analgesia in orthopedic surgery has been the subject of limited research, particularly within the Indian healthcare context. Chiaretti and colleagues (2000) conducted a pioneering study comparing pre-emptive analgesia with tramadol and fentanyl in pediatric neurosurgery, demonstrating that while both agents provided effective analgesia, fentanyl proved superior in the immediate postoperative period, whereas tramadol showed better efficacy when administered by continuous infusion with fewer adverse effects.

The concept of pre-emptive analgesia has evolved significantly since its initial description, with mounting evidence supporting its role in reducing postoperative pain intensity, analgesic consumption, and pain-related complications. Unlugenc and colleagues (2003) investigated pre-emptive analgesic efficacy of tramadol compared with morphine after major abdominal surgery, finding that tramadol administered after induction of anesthesia provided equivalent postoperative pain relief with similar recovery times and morphine consumption compared to pre-emptive morphine administration.

The Indian healthcare landscape presents unique considerations for pain management strategies, including patient demographics, cultural factors influencing pain expression, and economic

constraints that may affect analgesic choices. Studies conducted within the Indian population have demonstrated varying responses to analgesic interventions, potentially influenced by genetic polymorphisms affecting drug metabolism, particularly for tramadol which relies on CYP2D6 enzymatic conversion for optimal efficacy. These population-specific factors underscore the importance of conducting localized research to inform evidence-based clinical practices.

The timing and route of pre-emptive analgesic administration remain subjects of ongoing investigation. Power (2011) emphasized the importance of multimodal approaches to pain management, highlighting how newer analgesic formulations and delivery systems continue to evolve to optimize efficacy while minimizing adverse effects. The integration of pre-emptive strategies with established multimodal pain management protocols represents the current standard of care in progressive orthopedic surgery centers.

Quality of recovery and functional outcomes represent increasingly important endpoints in evaluating the success of perioperative pain management strategies. Beyond simple pain scores, contemporary research focuses on measures such as time to mobilization, patient satisfaction, length of hospital stay, and long-term functional recovery. Bourne and colleagues (2005) demonstrated the effectiveness of tramadol/acetaminophen combination tablets for postsurgical orthopedic pain, showing significant improvements in pain relief measures compared to placebo in patients undergoing arthroscopic procedures.

The aim of the study is to assess and compare the effectiveness of pre-emptive analgesia using tramadol versus fentanyl on post-operative pain management in patients undergoing orthopedic surgery.

Methodology

Study Design

This prospective, randomized, double-blind, controlled clinical trial.

Study Site

The study was conducted at Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, Krishna, Andhra Pradesh, a premier tertiary care teaching hospital with comprehensive orthopedic surgery services.

Study Duration

The study was conducted over a six-month period from April 2015 to September 2015.

Sampling and Sample Size

A systematic sampling approach was employed to recruit eligible patients undergoing elective orthopedic surgery during the study period. Sample size calculation was performed using statistical software with power analysis, considering a desired power of 80%, alpha error of 0.05, and clinically significant difference in pain scores of 2 points on the visual analog scale based on preliminary data and literature review. The calculation indicated a requirement of 25 patients per group to detect meaningful differences between interventions. To account for potential dropouts, protocol violations, and loss to follow-up, a total of 90 patients were recruited and randomly allocated to three groups of 30 patients each: tramadol group receiving intravenous tramadol 2 mg/kg, fentanyl group receiving intravenous fentanyl 2 μg/kg, and control group receiving equivalent volume of normal saline as placebo. Recruitment continued systematically until the predetermined sample size was achieved, ensuring adequate statistical power for meaningful clinical conclusions.

Inclusion and Exclusion Criteria

Inclusion criteria comprised patients aged 18-65 years of either gender scheduled for elective orthopedic surgery under general anesthesia, with American Society of Anesthesiologists (ASA) physical status classification I or II, and who provided written informed consent for participation.

Patients were required to have adequate cognitive function to understand study procedures and utilize pain assessment scales effectively. Exclusion criteria included patients with known hypersensitivity or allergic reactions to tramadol, fentanyl, or any study medications, history of chronic pain syndromes or regular analgesic use within 48 hours before surgery, psychiatric disorders or cognitive impairment that could affect pain assessment, significant cardiovascular disease including arrhythmias or heart failure, respiratory compromise including asthma or chronic obstructive pulmonary disease, hepatic or renal insufficiency that could affect drug metabolism, pregnancy or breastfeeding, history of substance abuse or dependence, patients receiving medications known to interact with study drugs including monoamine oxidase inhibitors or serotonin reuptake inhibitors, emergency surgical procedures, and patients unable to provide informed consent or participate in follow-up assessments.

Data Collection Tools and Techniques

Data collection was performed using standardized case record forms specifically designed and validated for this study. Pain assessment was conducted using the Visual Analog Scale (VAS) ranging from 0 representing no pain to 10 representing worst imaginable pain, with patients marking their pain intensity at predetermined time intervals. Hemodynamic monitoring included continuous assessment of heart rate, systolic and diastolic blood pressure, respiratory rate, and oxygen saturation using standard perioperative monitoring equipment calibrated according to manufacturer specifications. Side effect monitoring was performed using a comprehensive checklist documenting nausea, vomiting, sedation scores using the Ramsay Sedation Scale, respiratory depression defined as respiratory rate less than 10 breaths per minute or oxygen saturation below 95%, pruritus, and any allergic reactions. Rescue analgesic requirements were meticulously recorded, including type, dose, timing, and total consumption of additional pain medications. Patient satisfaction was assessed using a validated five-point Likert scale ranging from very dissatisfied to very satisfied. All assessments were performed by trained nursing personnel who remained blinded to group allocation throughout the study period, with inter-rater reliability established through training sessions and periodic calibration exercises.

Data Management and Statistical Analysis

Data were systematically collected, coded, and entered into a computerized database using Statistical Package for Social Sciences (SPSS) version 20.0 software. Data quality assurance measures included double data entry, range checks, and logical consistency verification to identify and correct any inconsistencies or missing values. Descriptive statistics were calculated for all variables, with continuous variables presented as mean ± standard deviation for normally distributed data and median with interquartile range for non-normally distributed data, while categorical variables were expressed as frequencies and percentages. Normality of data distribution was assessed using the Kolmogorov-Smirnov test. Between-group comparisons for continuous variables were performed using one-way analysis of variance (ANOVA) with post-hoc Tukey's honestly significant difference test for multiple comparisons when data were normally distributed, or Kruskal-Wallis test with Mann-Whitney U test for pairwise comparisons when data were non-normally distributed. Chi-square test or Fisher's exact test was used for categorical variables as appropriate. Repeated measures A p-value of less than 0.05 was considered statistically significant for all comparisons. Intention-to-treat analysis was performed to include all randomized patients in the final analysis, with appropriate methods such as last observation carried forward or multiple imputation employed for handling missing data.

Ethical Considerations

The study protocol underwent rigorous review and received approval from the Institutional Ethics Committee of Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation prior to patient recruitment. The study was conducted in strict accordance with the Declaration of Helsinki principles and Good Clinical Practice guidelines established by the International Conference on

Harmonisation. Written informed consent was obtained from all participants after providing comprehensive information about study objectives, procedures, potential risks and benefits, alternative treatments, and their rights as research participants.

Results:

Table 1: Demographic and Clinical Characteristics of Study Participants

Parameter		Tramadol Group (n=30)	Fentanyl Group (n=30)	Control Group (n=30)	p-value
Age (years), mean ± SD		42.3 ± 12.8	44.1 ± 11.6	43.7 ± 13.2	0.782
Gender, n (%)	Male	18 (60.0)	16 (53.3)	19 (63.3)	0.654
	Female	12 (40.0)	14 (46.7)	11 (36.7)	
Weight (kg), mean ± SD		68.4 ± 8.7	66.8 ± 9.3	69.2 ± 8.1	0.512
ASA Status	I	19 (63.3)	20 (66.7)	18 (60.0)	0.891
	II	11 (36.7)	10 (33.3)	12 (40.0)	
Surgery Type, n (%)	Knee arthroscopy	12 (40.0)	13 (43.3)	11 (36.7)	0.743
	Hip replacement	8 (26.7)	7 (23.3)	9 (30.0)	
	Fracture fixation	10 (33.3)	10 (33.3)	10 (33.3)	
Duration of surgery (min), mean ± SD		125.6 ± 28.4	128.3 ± 31.2	123.9 ± 26.8	0.823



Fig: 1

Table 2: Visual Analog Scale (VAS) Pain Scores at Different Time Points

Time Point	Tramadol Group (n=30)	Fentanyl Group (n=30)	Control Group (n=30)	p-value
Baseline (pre-op)	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	1.000
1 hour post-op	2.8 ± 1.2*	2.1 ± 0.9*†	5.4 ± 1.8	<0.001
2 hours post-op	3.2 ± 1.4*	2.6 ± 1.1*†	6.1 ± 2.1	<0.001
4 hours post-op	3.7 ± 1.6*	3.9 ± 1.5*	6.8 ± 2.3	<0.001
6 hours post-op	4.1 ± 1.8*	4.8 ± 1.9*	7.2 ± 2.5	<0.001
12 hours post-op	4.6 ± 2.1*	5.3 ± 2.2*	7.6 ± 2.8	<0.001
24 hours post-op	3.9 ± 1.7*	4.2 ± 1.8*	6.4 ± 2.4	<0.001

*Significantly different from control group ($p<0.05$) †Significantly different from tramadol group ($p<0.05$)



Fig: 2

Table 3: Hemodynamic Parameters During Study Period

Parameter	Tramadol Group (n=30)	Fentanyl Group (n=30)	Control Group (n=30)	p-value
Heart Rate (bpm)				
Baseline	78.4 ± 12.6	79.1 ± 11.8	77.9 ± 13.2	0.917

1 hour post-op	82.3 ± 14.1	76.8 ± 12.4*†	91.6 ± 16.8	<0.001
6 hours post-op	84.7 ± 13.9	79.2 ± 13.1*	88.4 ± 15.7	0.048
Systolic BP (mmHg)				
Baseline	128.6 ± 18.4	126.3 ± 17.2	129.8 ± 19.1	0.712
1 hour post-op	134.2 ± 20.1	118.7 ± 16.8*†	142.3 ± 22.6	<0.001
6 hours post-op	131.8 ± 19.3	124.1 ± 18.4*	138.9 ± 21.4	0.024
Respiratory Rate (per min)				
Baseline	16.2 ± 2.8	15.9 ± 2.6	16.4 ± 3.1	0.823
1 hour post-op	17.1 ± 3.2	14.8 ± 2.9*†	18.6 ± 3.8	<0.001
6 hours post-op	16.8 ± 3.1	15.6 ± 2.8	17.9 ± 3.6	0.038

*Significantly different from control group ($p<0.05$) †significantly different from tramadol group ($p<0.05$)



Fig: 3

Table 4: Incidence of Side Effects and Adverse Events

Side Effect	Tramadol Group (n=30)	Fentanyl Group (n=30)	Control Group (n=30)	p-value
Nausea, n (%)	8 (26.7)	12 (40.0)	6 (20.0)	0.189
Vomiting, n (%)	3 (10.0)	7 (23.3)*	2 (6.7)	0.124
Sedation (Ramsay ≥3), n (%)	4 (13.3)	14 (46.7)*†	2 (6.7)	<0.001
Respiratory depression, n (%)	0 (0.0)	3 (10.0)*	0 (0.0)	0.038
Pruritus, n (%)	2 (6.7)	8 (26.7)*†	1 (3.3)	0.016
Dizziness, n (%)	6 (20.0)	4 (13.3)	3 (10.0)	0.528
Constipation, n (%)	5 (16.7)	9 (30.0)	4 (13.3)	0.235
Total patients with ≥1 side effect	18 (60.0)	23 (76.7)*	12 (40.0)	0.012

*Significantly different from control group ($p<0.05$) †significantly different from tramadol group ($p<0.05$)



Fig: 4

Table 5: Rescue Analgesic Requirements and Time to First Request

Parameter	Tramadol Group (n=30)	Fentanyl Group (n=30)	Control Group (n=30)	p-value
Time to first analgesic request (hours), mean ± SD	6.8 ± 2.4*	4.2 ± 1.8*†	2.1 ± 0.9	<0.001
Total rescue analgesic doses in 24h, mean ± SD	2.3 ± 1.4*	3.1 ± 1.6*†	4.8 ± 2.2	<0.001
Patients requiring rescue analgesia, n (%)	22 (73.3)*	26 (86.7)	29 (96.7)	0.017
Total morphine equivalent (mg), mean ± SD	18.4 ± 11.2*	24.8 ± 12.9*†	38.4 ± 16.7	<0.001
Diclofenac doses required, mean ± SD	1.8 ± 1.2*	2.4 ± 1.4*	3.6 ± 1.8	<0.001

*Significantly different from control group ($p<0.05$) †Significantly different from tramadol group ($p<0.05$)



Fig: 5

Table 6: Patient Satisfaction Scores and Recovery Parameters

Parameter	Tramadol Group (n=30)	Fentanyl Group (n=30)	Control Group (n=30)	p-value
Patient Satisfaction Score (1-5), mean ± SD	4.2 ± 0.8*	3.8 ± 0.9*†	2.4 ± 1.1	<0.001

Time to mobilization (hours), mean ± SD	8.4 ± 2.6*	10.2 ± 3.1*†	12.8 ± 4.2	<0.001
Length of hospital stay (days), mean ± SD	2.8 ± 1.2*	3.2 ± 1.4*	4.1 ± 1.8	0.008
Sleep quality score (1-10), mean ± SD	7.3 ± 1.6*	6.8 ± 1.8*	4.9 ± 2.1	<0.001
Overall recovery score (1-10), mean ± SD	8.1 ± 1.4*	7.6 ± 1.7*	5.8 ± 2.3	<0.001

*Significantly different from control group ($p<0.05$) †Significantly different from tramadol group ($p<0.05$)



Fig: 6

Discussion

The demographic and clinical characteristics presented in Table 1 demonstrate successful randomization with no significant differences between the three study groups in terms of age, gender distribution, weight, ASA physical status, surgery type, and duration of surgery (all $p>0.05$). This baseline comparability ensures that observed differences in outcomes can be attributed to the interventions rather than confounding factors. The mean age of participants (42-44 years) and predominance of male patients (53-63%) are consistent with typical orthopedic surgery populations reported in previous studies (Bourne et al., 2005; Sekar et al., 2004). The distribution of surgical procedures, with knee arthroscopy being the most common (36-43%), followed by fracture fixation and hip replacement, reflects the case mix typically encountered in tertiary care orthopedic centers.

Table 2 reveals significant differences in VAS pain scores between groups, with both tramadol and fentanyl groups demonstrating superior pain control compared to the control group across all postoperative time points ($p<0.001$). The fentanyl group showed significantly lower pain scores at 1 and 2 hours postoperatively compared to the tramadol group ($p<0.05$), indicating more rapid onset of analgesic effect. However, this advantage diminished at later time points, with pain scores becoming comparable between the two active treatment groups by 4-6 hours. These findings align with the pharmacokinetic profiles of both drugs, where fentanyl's rapid onset but shorter duration contrasts with tramadol's slower onset but more sustained effect (Grond & Sablotzki, 2004).

The superior early analgesic effect of fentanyl observed in our study is consistent with the findings of Chiaretti and colleagues (2000), who reported that fentanyl provided better immediate postoperative pain control in pediatric neurosurgery. However, the sustained analgesic effect demonstrated by tramadol throughout the 24-hour observation period supports the conclusions of Unlugenc et al. (2003), who found that pre-emptive tramadol provided equivalent pain relief with similar morphine consumption compared to pre-emptive morphine in major abdominal surgery.

The peak pain scores observed in the control group (7.6 ± 2.8 at 12 hours) underscore the significant pain burden associated with orthopedic surgery and highlight the clinical importance of effective pre-emptive analgesia. The consistent pain reduction achieved by both active interventions throughout the study period demonstrates the clinical efficacy of pre-emptive analgesia, supporting the theoretical framework established by Wall (1988) regarding prevention of central sensitization.

Table 3 demonstrates important differences in hemodynamic responses between groups. The fentanyl group showed significantly greater hemodynamic stability with lower heart rates and blood pressure at 1 and 6 hours postoperatively compared to both tramadol and control groups. This enhanced cardiovascular stability likely reflects fentanyl's potent analgesic effect and its influence on sympathetic nervous system activation. Conversely, the control group exhibited expected stress responses with elevated heart rate and blood pressure, consistent with inadequate pain control.

The respiratory rate data reveals a concerning trend in the fentanyl group, with lower respiratory rates compared to other groups, although no episodes of clinically significant respiratory depression occurred. This finding is consistent with fentanyl's known respiratory depressant effects and emphasizes the importance of careful monitoring when using potent opioids for pre-emptive analgesia (Pandey et al., 2004). The tramadol group maintained more stable respiratory parameters while still providing effective analgesia, supporting its safety profile in perioperative settings.

The side effect profile presented in Table 4 reveals important safety differences between interventions. The fentanyl group experienced significantly higher incidence of sedation (46.7% vs 13.3%, $p<0.001$), respiratory depression (10.0% vs 0%, $p=0.038$), and pruritus (26.7% vs 6.7%, $p=0.016$) compared to the tramadol group. These findings are consistent with fentanyl's opioid receptor-mediated effects and align with previous reports by Viitanen and Annila (2001), who noted similar side effect patterns with opioid analgesics in surgical patients.

The higher incidence of nausea and vomiting in the fentanyl group, while not statistically significant in our study, corresponds to known opioid-related adverse effects. Tramadol's more favorable side effect profile can be attributed to its unique dual mechanism of action and lower affinity for opioid receptors, resulting in reduced classical opioid-related adverse events while maintaining analgesic efficacy (Rosenberg, 2009).

The overall incidence of patients experiencing at least one side effect was significantly higher in the fentanyl group (76.7%) compared to tramadol (60.0%) and control (40.0%) groups, highlighting the trade-off between analgesic efficacy and adverse events commonly encountered with potent opioids.

Table 5 demonstrates significant opioid-sparing effects for both active interventions. The tramadol group showed superior performance with the longest time to first analgesic request (6.8 ± 2.4 hours vs 4.2 ± 1.8 hours for fentanyl and 2.1 ± 0.9 hours for control, $p<0.001$). This prolonged analgesic duration supports tramadol's utility for sustained postoperative pain management, consistent with findings by Tuncer et al. (2007) in arthroscopic knee surgery.

The significantly reduced total morphine equivalent consumption in both active treatment groups compared to control (18.4 mg and 24.8 mg vs 38.4 mg respectively) demonstrates clinically meaningful opioid-sparing effects. This reduction is particularly relevant given current concerns about opioid-related adverse events and the emphasis on multimodal analgesia approaches (Kehlet & Dahl, 2003). The tramadol group's superior performance in reducing both rescue analgesic requirements and morphine equivalent consumption suggests its potential role as a cornerstone of multimodal pain management protocols.

Table 6 reveals significant improvements in patient-centered outcomes for both active treatment groups. Patient satisfaction scores were highest in the tramadol group (4.2 ± 0.8), followed by fentanyl (3.8 ± 0.9), and lowest in the control group (2.4 ± 1.1, $p<0.001$). This pattern reflects the balance between analgesic efficacy and side effect burden experienced by patients.

The enhanced recovery parameters demonstrated by both active interventions, including earlier mobilization, shorter hospital stays, and improved sleep quality, have significant clinical and economic implications. The tramadol group's superior performance in time to mobilization (8.4 vs 10.2 hours for fentanyl) may be attributed to its more favorable side effect profile, particularly lower sedation rates, allowing for earlier participation in rehabilitation activities.

These findings support the concept of enhanced recovery after surgery (ERAS) protocols, where effective pain management facilitates faster functional recovery and reduced healthcare resource utilization. The improved sleep quality scores in both active treatment groups are particularly relevant, as adequate sleep is crucial for healing and pain management (Kelly et al., 2001).

The overall results demonstrate that both tramadol and fentanyl provide effective pre-emptive analgesia compared to placebo, but with distinct clinical profiles. Fentanyl offers superior immediate pain control but is associated with higher rates of respiratory depression, sedation, and other opioid-related side effects. Tramadol provides more sustained analgesia with a superior safety profile and better patient-centered outcomes, making it particularly suitable for ambulatory and enhanced recovery protocols.

These findings align with the recommendations by Power (2011) for individualized analgesic selection based on patient factors, surgical requirements, and institutional protocols. The choice between tramadol and fentanyl for pre-emptive analgesia should consider the balance between immediate analgesic requirements and overall recovery goals, with tramadol appearing more suitable for procedures where sustained analgesia and minimal side effects are prioritized.

Conclusion

This prospective randomized controlled trial demonstrates that both tramadol and fentanyl provide superior pre-emptive analgesia compared to placebo in orthopedic surgery patients. While fentanyl offers more rapid onset of analgesia, tramadol provides more sustained pain relief with significantly fewer adverse effects. The tramadol group demonstrated the longest time to first rescue analgesic request, lowest total opioid consumption, highest patient satisfaction scores, and fastest mobilization times. Both interventions significantly reduced postoperative pain scores throughout the 24-hour observation period. Fentanyl was associated with higher incidences of sedation, respiratory depression, and pruritus, while maintaining comparable analgesic efficacy. The hemodynamic stability was best preserved in the fentanyl group, though respiratory parameters require careful monitoring. These findings support the clinical utility of pre-emptive analgesia in orthopedic surgery, with tramadol offering an optimal balance between efficacy and safety for most patients in this surgical population.

Recommendations

Based on study findings, tramadol 2 mg/kg intravenously administered after induction of anesthesia should be considered the preferred agent for pre-emptive analgesia in elective orthopedic surgery due to its superior safety profile and sustained analgesic effect. Fentanyl 2 μg/kg may be reserved for cases requiring immediate profound analgesia where enhanced monitoring is available. Implementation of

standardized pre-emptive analgesia protocols incorporating these agents should be integrated into institutional enhanced recovery pathways.

References

1. Antila, H., Manner, T., Kuurila, K., Salanterä, S., Kujala, R., & Aantaa, R. (2006). Ketoprofen and tramadol for analgesia during early recovery after tonsillectomy in children. *Paediatric Anaesthesia*, 16(5), 548-553. https://doi.org/10.1111/j.1460-9592.2005.01819.x
2. Arici, G., Karaman, H., Tapar, H., Kaya, Z., & Ertem, F. (2004). Analgesics for orthopedic postoperative pain. *American Journal of Orthopedics*, 33(3), 128-135. PMID: 15074460
3. Bourne, M. H., Rosenthal, N. R., Xiang, J., Jordan, D., & Kamin, M. (2005). Tramadol/acetaminophen tablets in the treatment of postsurgical orthopedic pain. *American Journal of Orthopedics*, 34(12), 592-597. PMID: 16450688
4. Chiaretti, A., Viola, L., Pietrini, D., Piastra, M., Savioli, A., Tortorolo, L., & Polidori, G. (2000). Preemptive analgesia with tramadol and fentanyl in pediatric neurosurgery. *Child's Nervous System*, 16(2), 93-99. https://doi.org/10.1007/s003810050019
5. Colwell, C. W., Jr. (2004). The use of the pain pump and patient-controlled analgesia in joint reconstruction. *American Journal of Orthopedics*, 33(5 Suppl), 10-12. PMID: 15195937
6. Ghai, B., Ram, J., Makkar, J. K., Wig, J., & Kaushik, S. (2009). Subtenon block compared to intravenous fentanyl for perioperative analgesia in pediatric cataract surgery. *Anesthesia & Analgesia*, 108(4), 1132-1138. https://doi.org/10.1213/ane.0b013e318198a3fd
7. Grond, S., & Sablotzki, A. (2004). Clinical pharmacology of tramadol. *Clinical Pharmacokinetics*, 43(13), 879-923. https://doi.org/10.2165/00003088-200443130-00004
8. Gupta, A., Kamath, S. S., Jain, V., Goyal, N., & Kumar, D. (2011). Evaluation of analgesic efficacy of tramadol versus pentazocine for post-operative pain relief. *Indian Journal of Anaesthesia*, 55(2), 129-133. https://doi.org/10.4103/0019-5049.79891
9. Kehlet, H., & Dahl, J. B. (2003). The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. *Anesthesia & Analgesia*, 97(5), 1303-1317. https://doi.org/10.1213/01.ANE.0000081734.58481.07
10. Kelly, D. J., Ahmad, M., & Brull, S. J. (2001). Preemptive analgesia II: Recent advances and current trends. *Canadian Journal of Anaesthesia*, 48(11), 1091-1101. https://doi.org/10.1007/BF03020378
11. Mitra, S., Kaushal, H., & Gupta, R. K. (2011). Evaluation of analgesic efficacy of intra-articular bupivacaine, bupivacaine plus fentanyl, and bupivacaine plus tramadol after arthroscopic knee surgery. *Arthroscopy*, 27(12), 1637-1643. https://doi.org/10.1016/j.arthro.2011.08.295
12. Moyao-García, D., Hernández-Palacios, J. C., Ramírez-Mora, J. C., & Nava-Ocampo, A. A. (2009). A pilot study of nalbuphine versus tramadol administered through continuous intravenous infusion for postoperative pain control in children. *Acta Biomedica*, 80(2), 124-130. PMID: 19848049
13. Ozyilmaz, K., Ayoglu, H., Okyay, R. D., Yurtlu, S., Koksal, B., Hanci, V., Erdogan, G., & Turan, I. O. (2012). Postoperative analgesic effects of wound infiltration with tramadol and levobupivacaine in lumbar disk surgeries. *Journal of Neurosurgical Anesthesiology*, 24(4), 331-335. https://doi.org/10.1097/ANA.0b013e3182611a1d
14. Pandey, C. K., Priye, S., Singh, S., Singh, U., Singh, R. B., & Singh, P. K. (2004). Preemptive use of gabapentin significantly decreases postoperative pain and rescue analgesic requirements in laparoscopic cholecystectomy. *Canadian Journal of Anaesthesia*, 51(4), 358-363. https://doi.org/10.1007/BF03018240
15. Power, I. (2011). An update on analgesics. *British Journal of Anaesthesia*, 107(1), 19-24. https://doi.org/10.1093/bja/aer126
16. Remérand, F., Le Tendre, C., Baud, A., Couvret, C., Pourrat, X., Favard, L., Laffon, M., & Fusciardi, J. (2009). The early and delayed analgesic effects of ketamine after total hip

arthroplasty: a prospective, randomized, controlled, double-blind study. *Anesthesia & Analgesia*, 109(6), 1963-1971. https://doi.org/10.1213/ANE.0b013e3181bdc8a0

17. Rosenberg, M. T. (2009). The role of tramadol ER in the treatment of chronic pain. *International Journal of Clinical Practice*, 63(10), 1531-1543. https://doi.org/10.1111/j.1742-1241.2009.02161.x
18. Schnitzer, T. (2003). The new analgesic combination tramadol/acetaminophen. *European Journal of Anaesthesiology Supplement*, 28, 13-17. PMID: 12785456
19. Sekar, C., Rajasekaran, S., Kannan, R., Reddy, S., Shetty, T. A., & Pithwa, Y. K. (2004). Preemptive analgesia for postoperative pain relief in lumbosacral spine surgeries: a randomized controlled trial. *The Spine Journal*, 4(3), 261-264. https://doi.org/10.1016/j.spinee.2003.11.009
20. Smith, A. B., Ravikumar, T. S., Kamin, M., Jordan, D., Xiang, J., Rosenthal, N., & CAPSS-115 Study Group. (2004). Combination tramadol 37.5 mg/acetaminophen 325 mg tablets versus combination codeine 30 mg/acetaminophen 300 mg tablets in the treatment of chronic non-cancer pain. *American Journal of Surgery*, 187(4), 521-527. https://doi.org/10.1016/j.amjsurg.2003.12.038
21. Tuncer, B., Erkorkmaz, U., Tekdemir, I., & Oktay, Z. A. (2007). Preemptive intraarticular tramadol for pain control after arthroscopic knee surgery. *Agri*, 19(1), 42-49. PMID: 17457706
22. Unlugenc, H., Ozalevli, M., Gunes, Y., Guler, T., & Isik, G. (2003). Pre-emptive analgesic efficacy of tramadol compared with morphine after major abdominal surgery. *British Journal of Anaesthesia*, 91(2), 209-213. https://doi.org/10.1093/bja/aeg163
23. Viitanen, H., & Annila, P. (2001). Analgesic efficacy of tramadol 2 mg kg^{-1} for paediatric day-case adenoidectomy. *British Journal of Anaesthesia*, 86(4), 572-575. https://doi.org/10.1093/bja/86.4.572
24. Wall, P. D. (1988). The prevention of postoperative pain. *Pain*, 33(3), 289-290. https://doi.org/10.1016/0304-3959(88)90286-2
25. Zeidan, A., Kassem, R., Nahleh, N., Maaliki, H., El-Khatib, M., Struys, M. M., & Baraka, A. (2008). Intraarticular tramadol-bupivacaine combination prolongs the duration of postoperative analgesia after outpatient arthroscopic knee surgery. *Anesthesia & Analgesia*, 107(1), 292-299. https://doi.org/10.1213/ane.0b013e31816ba364